Chen Xiaochen

Dr. Chen Xiaochen


Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2019 in The Lancet HIV
Verified
Journal Article
Closed access
HLHaijiang Lin
Haijiang Lin
YDYingying Ding
Yingying Ding
CNChenxi Ning
Chenxi Ning
XQXiaotong Qiao
Xiaotong Qiao
CXChen Xiaochen
Chen Xiaochen
NHNa He
Na He

1 April 2024 in JAMA Network Open
Verified
Journal Article
Open access
PDF file
SCShan Chen
Shan Chen
JSJianhua Sheng
Jianhua Sheng
FYFuzhong Yang
Fuzhong Yang
YQYi Qiao
Yi Qiao
WWWenzheng Wang
Wenzheng Wang
YTYingying Tang
Yingying Tang
Importance: Bipolar mania is a common disabling illness. Electroconvulsive therapy (ECT) is an effective treatment for patients with severe mania, though it is limited by the risk of cognitive adverse effects. Magnetic seizure therapy (MST) as an alternative treatment to ECT for bipolar mania has not yet been reported.Objective: To compare the effectiveness and cognitive adverse effects of MST and ECT in bipolar mania.Design, Setting, and Participants: This randomized clinical trial was conducted at the Shanghai Mental Health Center from July 1, 2017, through April 26, 2021. Forty-eight patients with bipolar mania were recruited and randomly allocated to receive MST or ECT. The data analysis was performed from June 5, 2021, through August 30, 2023.Interventions: Patients completed 2 or 3 sessions of MST or ECT per week for a total of 8 to 10 sessions. The MST was delivered at 100% device output with a frequency of 75 Hz over the vertex.Main Outcomes and Measures: The primary outcomes were reduction of total Young Manic Rating Scale (YMRS) score and response rate (more than 50% reduction of the total YMRS score compared with baseline). An intention-to-treat (ITT) analysis and repeated-measures analyses of variance were conducted for the primary outcomes.Results: Twenty patients in the ECT group (mean [SD] age, 31.6 [8.6] years; 12 male [60.0%]) and 22 patients in the MST group (mean [SD] age, 34.8 [9.8] years; 15 male [68.2%]) were included in the ITT analysis. The response rates were 95.0% (95% CI, 85.4%-100%) in the ECT group and 86.4% (95% CI, 72.1%-100%) in the MST group. The YMRS reduction rate (z = −0.82; 95% CI, −0.05 to 0.10; P = .41) and response rate (χ2 = 0.18; 95% CI, −0.13 to 0.31; P = .67) were not significantly different between the groups. The time-by-group interaction was significant for the language domain (F1,24 = 7.17; P = .01), which was well preserved in patients receiving MST but worsened in patients receiving ECT. No serious adverse effects were reported in either group.Conclusions and Relevance: These findings suggest that MST is associated with a high response rate and fewer cognitive impairments in bipolar mania and that it might be an alternative therapy for the treatment of bipolar mania.Trial Registration: ClinicalTrials.gov Identifier: NCT03160664

CXChen Xiaochen
Chen Xiaochen
XLXing Liu
Xing Liu
SDSong Duan
Song Duan
RTRenhai Tang
Renhai Tang
SZSujuan Zhou
Sujuan Zhou
NHNa He
Na He
Background: HIV and HCV coinfection leads to accelerated liver fibrosis, in which microbial translocation and systemic inflammation might play important roles. Objective: This study aimed to provide an extensive profile of the plasma microbial translocation and inflammation biomarkers associated with advanced liver fibrosis among HIV–HCV-coinfected patients. Methods: This cross-sectional study recruited 343 HIV–HCV-coinfected patients on combination antiretroviral therapy (cART) from a rural prefecture of Yunnan province in Southwest China. The plasma concentrations of sCD14 and 27 cytokines and chemokines were assayed and compared against advanced or mild levels of liver fibrosis. Results: Of the 343 HIV–HCV-coinfected patients, 188 (54.8%) had severe or advanced liver fibrosis (FIB-4 > 3.25). The patients with advanced liver fibrosis (FIB-4 > 3.25 vs. FIB-4 ≤ 3.25) had higher plasma levels of interleukin (IL)-1β, IL-6, IL-7, IL-9, IL-12, IL-15, IL-17, granulocyte macrophage colony stimulating factor (GM-CSF), Interferon-γ (IFN-γ), tumor necrosis factor (TNF-α), IL-4, IL-10, IL-13, fibroblast growth factor 2 (FGF-basic), and Monocyte chemoattractant protein-1 (MCP-1). Multivariable logistic regression models showed that advanced liver fibrosis was associated with an increased plasma level of IL-1β, IL-6, IL-7, IL-12, IL-17, GM-CSF, IFN-γ, IL-4, IL-10, MCP-1, Eotaxin, and FGF-basic, with FGF-basic continuing to be positively and significantly associated with advanced liver fibrosis, after Bonferroni correction for multiple comparisons (adjusted odds ratio (aOR) = 1.92; 95%CI: 1.32–2.81; p = 0.001). Plasma sCD14 was also significantly associated with advanced liver fibrosis (aOR = 1.13; 95%CI: 1.01–1.30; p = 0.049). Conclusions: HIV–HCV-coinfected patients are living with a high prevalence of advanced liver fibrosis which coexists with a mixture of elevated plasma inflammation and microbial translocation biomarkers. The significant associations of advanced liver fibrosis with FGF-basic and sCD14 may reveal pathogenic mechanisms and potential clinical intervention targets for liver fibrosis in HCV–HIV coinfection.

2 August 2022 in Food Frontiers
Verified
Journal Article
Open access
WLWenwen Lv
Wenwen Lv
XTXiyang Tan
Xiyang Tan
CXChen Xiaochen
Chen Xiaochen
THTingting Hu
Tingting Hu
JJJiayuan Jiang
Jiayuan Jiang
BQBiyun Qian
Biyun Qian
The protocol describes the first study evaluating the treatment of metabolism‐associated fatty liver disease (MAFLD). MAFLD, formerly known as nonalcoholic fatty liver disease, was renamed by an internationally renowned liver disease expert group in 2020. MAFLD contains three types: overweight/obesity (A type), type 2 diabetes mellitus (B type), or evidence of metabolic dysregulation (C type). There is a lack of effective therapeutic drugs. We found that D‐limonene, a food additive in China, has potential activity on the A type of MAFLD through animal studies. Then, we designed an exploratory, single‐center, double‐blind, placebo‐controlled, randomized clinical trial for the evaluation of limonene capsules (marketed product in China) on regulating A type of MAFLD and analysis of the TCM constitution (DLMAFLD‐TCM). A total of 60 patients with A type of MAFLD will be randomly assigned to a treatment arm with (n = 30) or without (n = 30) Food Frontiers for Review Only limonene (placebo) for 12 weeks. The primary end point will be assessed at two end points combined for A type: changes in the controlled attenuation parameter and body mass index at baseline and 12 weeks after administration. The study procedures and informed consent form were approved by the hospital. We detail the protocol and the statistical analysis plan of the trial prior to study completion, which is for further study. This trial is registered in the Chinese Clinical Trial Registry (ChiCTR2000035888).

28 February 2019 in BioScience Trends
Verified
Journal Article
Closed access
PDF file
CXChen Xiaochen
Chen Xiaochen
XLXing Liu
Xing Liu
RTRenhai Tang
Renhai Tang
RYRunhua Ye
Runhua Ye
YYYuecheng Yang
Yuecheng Yang
NHNa He
Na He
End-stage liver disease (ESLD) is among leading causes of death for people living with HIV and HCV. Little is known how liver fibrosis score predicts mortality in HIV/HCV co-infected population under combination antiretroviral therapy (cART). A retrospective cohort study of 691 HIV/HCV co-infected patients receiving cART in Yunnan, China from 2005 to 2016 was carried out to explore the association between Fibrosis-4 index (FIB-4) and all-cause mortality. Cox proportional hazard models were used to estimate the hazard ratios (HRs) for FIB-4 and covariates. After a median follow-up of 4.8 years with a total follow-up time of 3,696 person-years (PY), 131 deaths occurred and the all-cause mortality was 3.5 per 100 PY. The mortality was 2.9 (95% CI: 2.3-3.5)/100 PY for the FIB-4 ≤ 3.25 group and 5.8 (4.2-7.4)/100 PY for the FIB-4 > 3.25 group at baseline. People with FIB-4 changed from mild to advanced group showed HR of 1.81 (95% CI: 1.01-3.25) for death, and with FIB-4 sustaining advanced showed HR of 3.11 (1.75-5.54), both compared to those with FIB-4 remained mild, while lower risk of death was observed among married people (HR = 0.63, 95% CI: 0.41-0.99) compared to unmarried, among those with most recent CD4+ T cell counts between 200 and 350 cells/μL (0.50, 0.30-0.86) and > 350 cells/μL (0.25, 0.15-0.41) compared to CD4 under 200 cells/μL. Advanced and progressive liver fibrosis is a strong predictor of all-cause mortality in HIV/HCV co-infected patients under cART in China.
1

12 August 2024 in Discover Oncology
Verified
Journal Article
Open access
PDF file
ZFzz Fan
zz Fan
BYBowen Yin
Bowen Yin
CXChen Xiaochen
Chen Xiaochen
GYGuowei Yang
Guowei Yang
WZWei Zhang
Wei Zhang
RLRong Liu
Rong Liu
Background: Hepatocellular carcinoma (HCC) is a leading cause of cancer-related deaths worldwide, characterized by high rates of angiogenesis and immune evasion. Paraspeckle genes, involved in gene regulation and RNA metabolism, have recently been linked to tumor progression. This study aims to elucidate the relationship between paraspeckle genes and HCC prognosis, focusing on SFPQ, DDX39B, and UBAP2. Methods: We analyzed HCC (LIHC) and prostate cancer (PRAD) samples from the TCGA database to explore the correlation between paraspeckle genes and angiogenesis. We conducted unsupervised clustering, risk scoring, and survival analysis to identify distinct patient groups and their clinical outcomes. Gene expression data were used to perform differential analysis and Gene Ontology (GO) enrichment. Results: Our analysis identified significant correlations between paraspeckle genes and angiogenesis across multiple cancer types. Elevated expression levels of SFPQ, DDX39B, and UBAP2 were associated with poor prognosis in HCC patients, and all of them has statistical significance. Unsupervised clustering of HCC samples based on paraspeckle gene expression revealed two distinct clusters, with high-risk patients exhibiting stronger immune suppression and tumor immune evasion. GO enrichment highlighted critical pathways related to angiogenesis and immune regulation. Additionally, a risk scoring model based on these genes effectively distinguished high-risk and low-risk patient groups, providing valuable prognostic insights. Conclusion: This study demonstrates that SFPQ, DDX39B, and UBAP2 are significantly associated with poor prognosis in HCC, likely due to their roles in promoting angiogenesis and immune suppression. These findings highlight the potential of paraspeckle genes as prognostic biomarkers and therapeutic targets, offering new avenues for personalized treatment strategies in HCC. Further research into their functional mechanisms and clinical applicability is crucial for advancing HCC treatment and improving patient outcomes.